Arrowhead Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ARWR Nasdaq 2836 arrowheadpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arrowhead Pharmaceuticals, Inc.

Arrowhead Plozasiran Data Supports Triglyceride Reduction And Valuation Upside Potential - Mar 29th, 2026 10:04 am
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo - Mar 28th, 2026 8:30 am
SRPT Stock Surges on Promising Early Results From siRNA Programs - Mar 26th, 2026 11:14 am
Johnson & Johnson Exits 3 Biotechs but Keeps Stakes in These Rumored Acquisition Targets - Mar 25th, 2026 11:10 am
Sarepta Therapeutics Zooms 20% Higher on Promising Clinical Data: Is SRPT Ready for a Bigger Breakout? - Mar 25th, 2026 7:44 am
Sarepta sees early success with RNAi drugs from Arrowhead - Mar 25th, 2026 5:03 am
Sarepta Plans FDA Filings Seeking Full Approval for Two DMD Therapies - Mar 20th, 2026 8:47 am
A Look At Arrowhead Pharmaceuticals (ARWR) Valuation As Recent Momentum Cools After A Strong Run - Mar 20th, 2026 4:03 am
Arrowhead Pharmaceuticals Inc. (ARWR): Billionaire Ken Fisher Bets Big on Pharma - Mar 17th, 2026 2:14 pm
SRPT Stock Up as Enrollment Begins in DMD Gene Therapy Safety Study - Mar 17th, 2026 8:35 am
Arrowhead (ARWR) FQ1 2026 Revenue Hits $264M as REDEMPLO Approval Marks Commercial Shift - Mar 14th, 2026 12:29 pm
Arrowhead Pharmaceuticals Teases Q3 Data Wave: SHASTA-3/4, RNAi Dimer and ARO-MAPT Readouts Ahead - Mar 10th, 2026 2:31 am
Arrowhead Pharmaceuticals Teases 2026 Catalysts, Waylivra Launch Momentum at TD Cowen Conference - Mar 4th, 2026 6:48 pm
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Cooling Share Price And Strong Long-Term Returns - Feb 28th, 2026 11:11 pm
Alpha-1 Antitrypsin Deficiency Research Report 2025-2035: Market Enters Growth Phase as Established Augmentation Therapies Converge with Advancing Gene and RNA Pipelines - Feb 27th, 2026 4:31 am
Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events - Feb 24th, 2026 5:30 am
Morgan Stanley Notes 2026 Sales From Arrowhead Pharmaceuticals, Inc. (ARWR)’s Familial Chylomicronemia Syndrome Likely Limited - Feb 17th, 2026 10:54 pm
ARWR: Strong Start for REDEMPLO Commercialization… - Feb 11th, 2026 4:42 am
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Strong 1 Year Shareholder Return - Feb 7th, 2026 10:05 am
Arrowhead price target lowered to $78 from $81 at Morgan Stanley - Feb 7th, 2026 8:40 am